VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 34 of Oncotarget features Figure 2, "Potential paradigm-shifting effect of a cancer stem cell (CSC) inhibitor on tumor chemoresistance," from Oronsky, et al.
|
|
Table of Contents
Research Papers
|
| Bufalin inhibits gastric cancer invasion and metastasis by downregulating Wnt/ASCL2 expression |
|
https://doi.org/10.18632/oncotarget.24157
|
| 23320-23333 |
|
| The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.25101
|
| 23334-23348 |
|
| The multifunctional protein YB1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors |
|
https://doi.org/10.18632/oncotarget.25158
|
| 23349-23365 |
|
| Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma |
|
https://doi.org/10.18632/oncotarget.25163
|
| 23366-23372 |
|
| Fenfluramine diminishes NMDA receptormediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors |
|
https://doi.org/10.18632/oncotarget.25169
|
| 23373-23389 |
|
| Pilot study of dovitinib in patients with von HippelLindau disease |
|
https://doi.org/10.18632/oncotarget.25171
|
| 23390-23395 |
|
| Antitumoral and antimetastatic activity of Maitake DFraction in triplenegative breast cancer cells |
|
https://doi.org/10.18632/oncotarget.25174
|
| 23396-23412 |
|
| A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2 |
|
https://doi.org/10.18632/oncotarget.25182
|
| 23413-23425 |
|
| Oxaliplatininduced blood brain barrier loosening: a new point of view on chemotherapyinduced neurotoxicity |
|
https://doi.org/10.18632/oncotarget.25193
|
| 23426-23438 |
|
| Brief report: RRx001 is a cMyc inhibitor that targets cancer stem cells |
|
https://doi.org/10.18632/oncotarget.25211
|
| 23439-23442 |
|
| Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma |
|
https://doi.org/10.18632/oncotarget.25215
|
| 23443-23450 |
|
| Forskolin increases the effect of everolimus on aromatase inhibitorresistant breast cancer cells |
|
https://doi.org/10.18632/oncotarget.25217
|
| 23451-23461 |
|
| Limited fibrosis accompanies triplenegative breast cancer metastasis in multiple model systems and is not a preventive target |
|
https://doi.org/10.18632/oncotarget.25231
|
| 23462-23481 |
|
| Indoleamine 23dioxygenase 1 and overall survival of patients diagnosed with esophageal cancer |
|
https://doi.org/10.18632/oncotarget.25235
|
| 23482-23493 |
|
| Identification of RECK as an evolutionarily conserved tumor suppressor gene for zebrafish malignant peripheral nerve sheath tumors |
|
https://doi.org/10.18632/oncotarget.25236
|
| 23494-23504 |
|
| The cyclindependent kinase inhibitor flavopiridol alvocidib inhibits metastasis of human osteosarcoma cells |
|
https://doi.org/10.18632/oncotarget.25239
|
| 23505-23518 |
|
| Breast cancer stem celllike cells generated during TGFβinduced EMT are radioresistant |
|
https://doi.org/10.18632/oncotarget.25240
|
| 23519-23531 |
|
| Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model |
|
https://doi.org/10.18632/oncotarget.25247
|
| 23532-23542 |
|
| Levels of miR126 and miR218 are elevated in ductal carcinoma in situ DCIS and inhibit malignant potential of DCIS derived cells |
|
https://doi.org/10.18632/oncotarget.25261
|
| 23543-23553 |
|
| Highly expressed placental miRNAs control key biological processes in human cancer cell lines |
|
https://doi.org/10.18632/oncotarget.25264
|
| 23554-23563 |
|
| Both the intratumoral immune and microbial microenvironment are linked to recurrence in human colon cancer: results from a prospective multicenter nodal ultrastaging trial |
|
https://doi.org/10.18632/oncotarget.25276
|
| 23564-23576 |
|
| miRNA122a regulation of gene therapy vectors targeting hepatocellular cancer stem cells |
|
https://doi.org/10.18632/oncotarget.25280
|
| 23577-23588 |
|
| Tolllike receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma |
|
https://doi.org/10.18632/oncotarget.25283
|
| 23589-23598 |
|
| Histogram analysis parameters of apparent diffusion coefficient reflect tumor cellularity and proliferation activity in head and neck squamous cell carcinoma |
|
https://doi.org/10.18632/oncotarget.25284
|
| 23599-23607 |
|
| The use of helical tomotherapy in the treatment of early stage breast cancer: indications tolerance efficacy—a single center experience |
|
https://doi.org/10.18632/oncotarget.25286
|
| 23608-23619 |
|
| A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival |
|
https://doi.org/10.18632/oncotarget.25306
|
| 23620-23627 |
|
| Clinical results of dynamic tumor tracking intensitymodulated radiotherapy with realtime monitoring for pancreatic cancers using a gimbal mounted linac |
|
https://doi.org/10.18632/oncotarget.25310
|
| 23628-23635 |
|
| Changes of signal transductivity and robustness of gene regulatory network in the carcinogenesis of leukemic subtypes via microarray sample data |
|
https://doi.org/10.18632/oncotarget.25318
|
| 23636-23660 |
|
| Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study |
|
https://doi.org/10.18632/oncotarget.25320
|
| 23661-23669 |
|
| Global isoformspecific transcript alterations and deregulated networks in clear cell renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.25330
|
| 23670-23680 |
|
| Development of a cellbased assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide |
|
https://doi.org/10.18632/oncotarget.25348
|
| 23681-23694 |
|
| Long noncoding RNA CCAT1 as a diagnostic and prognostic molecular marker in various cancers: a metaanalysis |
|
https://doi.org/10.18632/oncotarget.24923
|
| 23695-23703 |
|
| Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and metaanalysis of 14 trials |
|
https://doi.org/10.18632/oncotarget.25281
|
| 23704-23717 |
|
| Efficacy and tolerability of pharmacotherapy for poststroke depression: a network metaanalysis |
|
https://doi.org/10.18632/oncotarget.23891
|
| 23718-23728 |
Clinical Research Papers
|
| Safety and pharmacokinetics of DS6051b in Japanese patients with nonsmall cell lung cancer harboring ROS1 fusions: a phase I study |
|
https://doi.org/10.18632/oncotarget.25263
|
| 23729-23737 |
|
| Optimal hydration volume among highrisk patients with advanced congestive heart failure undergoing coronary angiography |
|
https://doi.org/10.18632/oncotarget.25315
|
| 23738-23748 |
|
| Prognostic factors of afatinib as a firstline therapy for advanced EGFR mutationpositive lung adenocarcinoma: a realworld large cohort study |
|
https://doi.org/10.18632/oncotarget.25255
|
| 23749-23760 |
Reviews
|
| Stromal cells in breast cancer as a potential therapeutic target |
|
https://doi.org/10.18632/oncotarget.25245
|
| 23761-23779 |
|
| p53 and metabolism: from mechanism to therapeutics |
|
https://doi.org/10.18632/oncotarget.25267
|
| 23780-23823 |
|
| Oxidative stress in female cancers |
|
https://doi.org/10.18632/oncotarget.25323
|
| 23824-23842 |
Corrections
|
| Correction: HOTAIR regulates HK2 expression by binding endogenous miR125 and miR143 in oesophageal squamous cell carcinoma progression |
|
https://doi.org/10.18632/oncotarget.25377
|
| 23843-23843 |
|
| Correction: Radiotherapy increases plasma levels of tumoral cellfree DNA in nonsmall cell lung cancer patients |
|
https://doi.org/10.18632/oncotarget.25378
|
| 23844-23844 |
Retraction
|
| Retraction: PDZcontaining 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation |
|
https://doi.org/10.18632/oncotarget.25033
|
| 23845-23845 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
